Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

NCT06015750 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision following FDA release from the PMR.

Conditions

Hypophosphatasia

Interventions

DRUG: methotrexate
DRUG: rituximab
DRUG: bortezomib
DRUG: IVIg
DRUG: Folic Acid

Sponsor

Alexion Pharmaceuticals, Inc.